Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEJ026: erlotinib plus bevacizumab versus erlotinib alone in untreated EGFR-mutant non-small cell lung cancer
jRCTs031180056Phase 3Completed
- Sponsor
- North East Japan Study Group
- Start
- Jun 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Erlotinib plus bevacizumab with Erlotinib monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Jun 2015; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180056.